Author Archives: Ashraf Malhas, PhD

A study finds that, contrary to some reports, the use of inhaled nitric oxide can be effective in treating premature infants with acute pulmonary hypertension. The study, “The efficacy of inhaled nitric oxide treatment in premature infants with acute pulmonary hypertension,” was published in the journal Early Human…

Supplemental oxygen use is associated with improved survival in a subpopulation of patients with pulmonary arterial hypertension (PAH), a study has found. Current guidelines that recommend oxygen supplementation therapy for PAH patients are based on early data that showed the benefits of long-term oxygen therapy in patients with…

The healthcare costs of Americans with pulmonary arterial hypertension (PAH) are about the same before and after treatment starts, mainly because high treatment costs offset fewer hospitalizations, a study shows. The research, “Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension…

A generic molecule that works by activating a mitochrondrial protein, dichloroacetate (DCA), was seen in a Phase 1 clinical trial to  reduce pulmonary arterial blood pressure and improve lung function in patients with pulmonary arterial hypertension (PAH). In PAH, cells of blood vessels adopt characteristics that are similar to cancer cells,…

Pulmonary artery dilation speeds up the progression of pediatric idiopathic and heritable pulmonary arterial hypertension (PAH), a Japanese study shows. Dilation of the main pulmonary artery (MPA) and narrowing of the peripheral pulmonary artery are both characteristic of PAH. Previous studies have shown that MPA dilation is linked to higher pulmonary artery…

Pulmonary arterial hypertension (PAH) is a rare complication of systemic lupus erythematosus (SLE) and is associated with the presence of specific autoantibodies, a study has found. PAH is a complex disease characterized by the constriction of pulmonary arteries. PAH can be associated with connective tissue diseases (CTDs) such as SLE. The…

The U.S. Food and Drug Administration (FDA) has declined SteadyMed Therapeutics‘ new drug application (NDA) for its Trevyent (treprostinil injection) therapy to treat pulmonary arterial hypertension (PAH). SteadyMed, with offices in San Ramon, California, and in Israel, had submitted its NDA in July 2017. But the application was denied on Aug. 31…